The team found that they could give thiotepa with ifosfamide, etoposide and rituximab.
Trial design
This was a phase 1 
and phase 2 trial. In total 36 people took part in this trial.
In phase 1 the first few people had a small dose of thiotepa with
ifosfamide, etoposide and rituximab. If all went well then the next few had a higher dose of thiotepa. And so on until the team found the best dose of thiotepa to give with ifosfamide, etoposide and rituximab.
In phase 2 everyone had this dose of thiotepa with ifosfamide, etoposide and rituximab.
Results
The research team wanted to find out how well this combination had helped. To do this they looked at what the intention to treat was when people joined the trial. This is called an intention to treat analysis . For this analysis there were 27 people. They found that it helped 14 people (52%).
Of these 14 people:
- there was no sign of the lymphoma in 9 (a complete response)
- the lymphoma had got better in 5 (a partial response)
The lymphoma had got worse in 4 people. This is called progressive disease.
The team were unable to include the remaining 9 people for a number of reasons. They include:
- death
- leaving the trial
- stopping treatment due to side effects
The team looked at the length of time people lived without any sign of the lymphoma getting worse. They found it was from 2 months to 6 months.
They also looked at the length of time that people lived after treatment. They found it was from 3 months to 9 months.
Side effects
The team looked at the worst side effects of treatment. The most common of these included:
- a drop in blood cells causing an increased risk of bruising, bleeding and infection
- a high temperature (fever) with a low number of white blood cells called neutrophils
- fits (seizure)
- confusion
- difficulty speaking
- headache
- low levels of phosphate, potassium, magnesium and albumin in the blood
- difficulty swallowing
Conclusion
The team concluded that thiotepa, ifosfamide, etoposide and rituximab can help people with CNS lymphoma:
- that has come back after treatment or
- when initial chemotherapy doesn’t work
However they say that for most people the outcome of treatment remains poor and new treatment plans are urgently needed.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed ) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
